Tandem Mobi gains FDA clearance for a tubeless option
A new cartridge and infusion set retain the existing pump, with a full US launch planned for the first half of 2027.

Tandem Diabetes Care has reported FDA clearance for a tubeless option for Tandem Mobi. A new cartridge and infusion set convert the existing pump into a wearable tubeless system.
Tubed use remains possible. The manufacturer describes up to seven days of wear with Control-IQ+ automated insulin delivery. Full US commercial launch is planned for the first half of 2027. Existing Mobi pumps are compatible, and in-warranty customers do not need a replacement pump, according to the company.
Context and evidence
The sets and cartridges are planned for pharmacy-only access for people with applicable insurance benefits. This concerns both hardware and a defined access channel. The planned launch date is separate from the clearance already granted; the source contains no independent head-to-head comparison with other tubeless systems.
What it means
The option adds a new wear configuration to an existing platform. Actual access will depend on launch, insurance benefits and medical suitability, not clearance alone.
Primary source: Original announcement. This report is based on company statements, not an independent clinical assessment.
More from Regulation
AI illustrationFDA clears AI software for coronary CT analysis
Syngo.CT Coronary Cockpit analyzes plaque and supports intervention planning. The clearance applies to the US market.
AI illustrationHugo surgical robot gains US clearance for general surgery
Medtronic expands the US indications for its robotic-assisted surgery platform; clearance is not proof of superior outcomes.
AI illustrationPhilips submits helium-free 3T MRI platform to the FDA
BlueSeal Horizon is under review, not cleared; “helium-free” describes operation with helium sealed inside the magnet.